biote (NASDAQ:BTMD) and Guardant Health (NASDAQ:GH) Head-To-Head Survey

Guardant Health (NASDAQ:GH – Get Free Report) and biote (NASDAQ:BTMD – Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, institutional ownership, profitability, risk and dividends.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Guardant Health and biote, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Guardant Health 1 0 24 1 2.96
biote 1 1 1 1 2.50

Guardant Health presently has a consensus target price of $190.88, indicating a potential upside of 33.22%. biote has a consensus target price of $2.50, indicating a potential upside of 152.53%. Given biote’s higher possible upside, analysts plainly believe biote is more favorable than Guardant Health.

Risk & Volatility

Guardant Health has a beta of 1.67, indicating that its stock price is 67% more volatile than the S&P 500. Comparatively, biote has a beta of 1.73, indicating that its stock price is 73% more volatile than the S&P 500.

Profitability

This table compares Guardant Health and biote’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Guardant Health -37.93% N/A -25.03%
biote -1.08% -8.61% 4.61%

Valuation & Earnings

This table compares Guardant Health and biote”s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Guardant Health $982.02 million 19.74 -$416.28 million ($3.68) -38.93
biote $192.22 million 0.18 $27.05 million ($0.10) -9.90

biote has lower revenue, but higher earnings than Guardant Health. Guardant Health is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

92.6% of Guardant Health shares are owned by institutional investors. Comparatively, 21.7% of biote shares are owned by institutional investors. 5.6% of Guardant Health shares are owned by company insiders. Comparatively, 32.4% of biote shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

biote beats Guardant Health on 8 of the 14 factors compared between the two stocks.

About Guardant Health

(Get Free Report)

Guardant Health is a precision oncology company that develops blood- and tissue-based tests to help guide cancer care. Founded in 2012 by Helmy Eltoukhy and AmirAli Talasaz, the company focuses on using genomic information to support cancer detection, treatment selection and disease monitoring. Its products include Guardant360 tests, which analyze tumor-related genetic changes to help inform treatment decisions, and Guardant Reveal, which is designed to detect residual or recurring cancer after treatment.

About biote

(Get Free Report)

Biote is a medical technology and services company focused on hormone optimization. It supports healthcare providers who offer bioidentical hormone replacement therapy (BHRT), including pellet-based treatment programs for eligible patients. The company’s services include provider training and education, patient and practice support, and hormone testing and treatment protocols. Biote also offers nutritional supplements and related wellness products through participating providers. Biote was founded in 2012 and serves a network of healthcare providers in the United States.

Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.